All treatments were administered BID.
*P value is based on treatment comparison of absolute mean change from baseline for BEVESPI AEROSPHERE vs placebo.
†In Trial 1, mean change from baseline in daily rescue albuterol use over 24 weeks was -0.5 puffs/day (baseline 3.4 puffs/day) with glycopyrrolate 18 mcg (n=449), -0.8 puffs/day (baseline 3.4 puffs/day) with formoterol fumarate 9.6 mcg (n=446), and 0.3 puffs/day (baseline 3.4 puffs/day) with placebo (n=218) (P<0.0001 for all active treatments vs placebo).
‡Trial 2 demonstrated a 31% reduction from baseline in rescue albuterol use vs placebo (P<0.0001). P value is based on treatment comparison of absolute mean change from baseline for BEVESPI AEROSPHERE vs placebo. In Trial 2, mean change from baseline in daily rescue albuterol use was -1.0 puffs/day over 24 weeks with BEVESPI AEROSPHERE (baseline 3.2 puffs/day, n=510), -0.4 puffs/day with glycopyrrolate 18 mcg (baseline 3.6 puffs/day, n=438), -0.7 puffs/day with formoterol fumarate 9.6 mcg (baseline 3.5 puffs/day, n=437), and 0.0 puffs/day with placebo (baseline 3.9 puffs/day, n=223) (P<0.01 for all active treatments vs placebo).
Please see Important Safety Information and full Prescribing Information, including Boxed WARNING available on website.
References: 1. BEVESPI AEROSPHERE [Package Insert]. Wilmington, DE: AstraZeneca; 2017. 2. Martinez FJ, Rabe KF, Ferguson GT, et al. Chest. 2017;151(2):340-357. 3. Data on File, REF-5037, AZPLP. 4. Data on File, REF-5036, AZPLP.